Naslov
Treatment outcomes and 5-year survival in patients with nontuberculous pulmonary disease, data from Croatian national registry

Autori
Mateja Jankovic Makek , Ivan Sabol , Ljiljana Zmak10 , Goran Glodic , Anamarija Sola , Ivana Mareković , Ljiljana Bulat Kardum3 , Brigita Ticac , Marina Payerl-Pal , Ante Marusic12 , Sanja Popović-Grle , Vesna Carevic2 , Drazen Strelec , Marko Jakopovic1 , Miroslav Samarzija1

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
28th European Congress of Clinical Microbiology and iNfectious Diseases

Mjesto i datum
Madrid, Španjolska, 21.04.2018. - 24.04.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
nontuberculous myconacteria, treatment, outcome

Sažetak
Background: Nontuberculous mycobacteria (NTM) are opportunistic pathogens that cause NTM pulmonary disease (NTM-PD). Given its’ complexity, randomized prospective clinical trials are hard to perform. We aimed to determine the characteristics of NTM-PD in Croatia, detect the possible risk factors favoring NTM-PD, record therapy outcomes and long term survival. Materials/methods: retrospective analysis of all Croatian residents with respiratory NTM isolate from 2006 to 2016. Definite NTM-PD was defined according to the guidelines of American Thoracic Society/Infectious Diseases Society of America. Treatment outcome (microbiological cure and complete/ partial resolution of symptoms) rates were calculated with regard to the received therapy: adequate (according to the guidelines) ; short duration adequate therapy (less than 12 months after culture conversion) ; tuberculosis protocol therapy ; inadequate (i.e. single anti-NTM agent)/no therapy). Results: medical records were available for 536 cases. Cases of active tuberculosis were excluded from further analyses. Out of remaining 472 cases, 141 were classified as definite NTM-PD. Most commonly encountered NTM species causing disease were Mycobacterium xenopi and M. avium complex. 37 (26.2%) had fibro-cavitary type, and 89 (63.1%) nodular-bronchiectatic type of disease, while the remaining 10.7% had other radiological finding. Compared to cases of colonization, patients with NTM-PD more likely had high-doses inhaled corticosteroid therapy (p=0.019), bronchiectasies (p<0.0001), low body mass index (p<0.0001), rheumatologic disorder (p=0.018), or prior history of TB (p=0.028). 35 (24.8%) received adequate NTM therapy, 14 (9.9%) short duration adequate regimen, 43 (30.5%) TB treatment protocol, while 47 (33.3%) received inappropriate therapy or no therapy. In patients who finished with planned treatment protocol, cure was achieved in 22 (62.9%) on TB treatment, 24 (82.8%) on adequate therapy and 8 (57.1%) on short duration adequate therapy. Of 37 patients receiving inadequate or no therapy who lived for at least 6 months after the diagnosis, 7 (18.9%) achieved spontaneous culture conversion during the follow up. 5-year survival in adequately treated patients amounted to 85% compared to 64% in those receiving any other type of therapy or no therapy (p=0036). Conclusions: only 25% of patient received therapy according to the guidelines. Adequate treatment significantly improved treatment outcome and 5- year survival of patients with NTM-PD

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA